Gilead Confirms Binding Deal for Ouro Medicines Acquisition, Commits Half of $1.675B Upfront
GILD sits 45% above its 52-week low of $93.37.
Summary
Gilead Sciences and Galapagos have entered a binding agreement to acquire Ouro Medicines, with Gilead committing to fund 50% of the $1.675 billion upfront payment and associated milestone payments. This definitive agreement confirms the previous Reuters report from March 23rd that Gilead was nearing a deal for Ouro Medicines. The acquisition is strategically important for Gilead, expanding its pipeline in autoimmune diseases through Ouro's first-in-class T-cell engager program. This material investment solidifies Gilead's commitment to diversifying its therapeutic areas. Investors will now monitor the integration of Ouro Medicines and the clinical development progress of the acquired T-cell engager program.
At the time of this announcement, GILD was trading at $135.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $169.3B. The 52-week trading range was $93.37 to $157.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.